Sana Biotechnology (NASDAQ:SANA) Shares Up 8.5% – What’s Next?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares were up 8.5% during mid-day trading on Thursday . The company traded as high as $3.78 and last traded at $3.8640. 339,700 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 3,225,221 shares. The stock had previously closed at $3.56.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Wedbush increased their target price on Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Tuesday, April 14th. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They issued a “buy” rating and a $16.00 price target for the company. Weiss Ratings cut shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Sunday, June 7th. Finally, Morgan Stanley reissued an “overweight” rating and set a $12.00 price objective on shares of Sana Biotechnology in a report on Friday, March 13th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Sana Biotechnology currently has an average rating of “Moderate Buy” and a consensus price target of $9.50.

Sana Biotechnology Stock Performance

The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -4.31 and a beta of 2.13. The stock has a 50-day moving average of $3.21 and a 200-day moving average of $3.67.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. As a group, research analysts expect that Sana Biotechnology, Inc. will post -0.59 earnings per share for the current fiscal year.

Institutional Trading of Sana Biotechnology

A number of large investors have recently modified their holdings of the company. Xponance LLC boosted its stake in Sana Biotechnology by 25.6% during the 4th quarter. Xponance LLC now owns 13,068 shares of the company’s stock valued at $53,000 after purchasing an additional 2,662 shares during the period. Creative Planning increased its stake in shares of Sana Biotechnology by 5.3% in the third quarter. Creative Planning now owns 54,177 shares of the company’s stock valued at $192,000 after purchasing an additional 2,719 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Sana Biotechnology by 29.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,944 shares of the company’s stock valued at $53,000 after purchasing an additional 2,943 shares during the period. Rockefeller Capital Management L.P. raised its holdings in shares of Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after buying an additional 4,088 shares during the last quarter. Finally, Polymer Capital Management US LLC raised its holdings in shares of Sana Biotechnology by 32.5% during the fourth quarter. Polymer Capital Management US LLC now owns 18,285 shares of the company’s stock valued at $74,000 after buying an additional 4,480 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.